Acute Interstitial Nephritis Associated with the Use of Mesalazine in Inflammatory Bowel Disease
Overview
Affiliations
Background: In the last 10 years several reports have linked oral 5-aminosalicylic acid (5-ASA) therapy to acute and chronic tubulointerstitial nephritis, but to our knowledge only 2 patients have been reported with terminal end-stage renal disease due to mesalazine (5-ASA). After 1 year of treatment with 5-ASA annual monitoring of serum creatinine is recommended.
Results: We report the development of end-stage renal disease in a patient 10 months after the last assessment of serum creatinine, which was normal at 71 micromol/l.
Conclusion: Because of this dangerous side effect, we would like to recommend 6-monthly assessment of renal function.
Monzani R, Gagliardi M, Clemente N, Saverio V, Panczyszyn E, Santoro C Biology (Basel). 2022; 11(11).
PMID: 36358275 PMC: 9687175. DOI: 10.3390/biology11111574.
Wang S, Zhou P, Li Z Front Pediatr. 2022; 10:808472.
PMID: 35615637 PMC: 9125087. DOI: 10.3389/fped.2022.808472.
Moss J, Parry C, Holt R, McWilliam S Eur J Med Res. 2022; 27(1):61.
PMID: 35488310 PMC: 9052675. DOI: 10.1186/s40001-022-00687-y.
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Murray A, Nguyen T, Parker C, Feagan B, MacDonald J Cochrane Database Syst Rev. 2020; 8:CD000543.
PMID: 32786164 PMC: 8189994. DOI: 10.1002/14651858.CD000543.pub5.
The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis.
Jia K, Tong X, Wang R, Song X Medicine (Baltimore). 2018; 97(51):e13792.
PMID: 30572537 PMC: 6319782. DOI: 10.1097/MD.0000000000013792.